# Thesis: Cross-Subsidization Math Determines Where AI Value Accrues

## Investment Take

Health systems run on cross-subsidization: elective procedures (22-25% margins) fund emergency care (-15% to -18% margins). One spinal fusion offsets three sepsis cases ([[An Analysis of DRG Profitability]]). AI that improves elective efficiency protects the cash cow. AI that reduces emergency costs saves money nobody was capturing anyway. Understanding this math determines where AI creates extractable value vs where it creates savings that disappear into the margin hole.

MA is at margin trough: -2.0% pre-tax margins (2025E), worst in 25+ years. Industry MLR reached 91% (+220bps YoY). UnitedHealth projected $6.5B more in medical costs than anticipated ([[Financial Performance of U.S. Health Insurers]]). Medical cost trends accelerated to 7.5-8.5%—fastest since mid-2000s—driven by GLP-1 ($50B extra pharmacy spending) and behavioral health (+45% utilization). But this creates embedded earnings opportunity: achieving 4.5% MA margins would boost sector EPS by 50%.

Health system CFOs think in portfolio terms, not service line ROI. They won't cut ortho to fund sepsis AI. Will Detwiler confirmed: CFOs responding "top 3 priority" to margin analytics by code/payer/physician ([[Will Detwiler and Emre Karatas]]). AI companies selling to the wrong buyer (CMO for clinical value vs CFO for margin protection) fail.

**How this evolved:**
- *2025-12-18:* DRG profitability analysis crystallized the insight. Health systems optimize around protecting high-margin service lines, not reducing costs on money-losers.
- *2025-12-21:* Added MA margin data. Cost trend acceleration (7.5-8.5%) + VBC adoption (34% of MA payments, up from 10.3% in 2017) validates cross-thesis with Specialty-VBC-Dynamics.

---

## Bull Case

- [x] **CFO pain is real and budgeted.** CFOs responding "top 3 priority" to margin analytics. Previous supply chain pitch got "we'll get around to it."
  - *Evidence:* [[Will Detwiler and Emre Karatas]] — CFO priority shift confirmed

- [ ] **First AI companies to understand this will win.** Selling margin protection to CFOs beats selling clinical improvement to CMOs.
  - *Evidence:* Needs validation — track which AI deals close and who championed internally

- [ ] **VBC transition creates opportunity.** As FFS margins compress, AI enabling VBC success becomes critical. 34% of MA payments now population-based.
  - *Evidence:* [[Financial Performance of U.S. Health Insurers]] — VBC at 34% of MA payments (up from 10.3% in 2017)

---

## Bear Case

- [ ] **Too fragmented.** Each health system has different economics. Hard to build scalable product.
  - *Evidence:* Needs validation — map service line economics across 10+ systems

- [ ] **Incumbents bundle.** Epic (274 AI customers) and Oracle bundle analytics with EHR. "Good enough" blocks specialized vendors.
  - *Evidence:* [[Texas antitrust case]] — Epic controls 90%+ records, distribution moat

- [ ] **Margin compression kills buyers.** If health systems can't afford anything, market shrinks. 30%+ operating negative margins.
  - *Evidence:* Needs monitoring — track software spending by margin quartile

---

## Startup Opportunities

**1. Elective Procedure Optimization Platform**
- OR scheduling, surgeon utilization, patient flow for high-margin procedures
- Why this follows: Protecting 22% margin procedures is CFO priority
- Sell to CFO: "Protect your cash cow service lines"
- Risk: Fragmented, each health system different

**2. Service Line Portfolio Analytics**
- Show health systems their cross-subsidization math
- Why this follows: CFOs need visibility into which AI investments protect vs which save money that doesn't exist
- Translucent's 5x growth ($625K→$1.8M) validates CFO demand
- Risk: Epic/Oracle bundle "good enough" analytics

**3. TEFCA-Native Analytics Aggregator**
- Exploit 2025 data interoperability mandates
- Why this follows: TEFCA breaks EHR lock-in; analytics can aggregate across Epic/Cerner/Allscripts
- Wedge: "Epic's analytics but across all your systems"
- Risk: EHR vendors improve native analytics, TEFCA enforcement delays

---

## Open Questions

**How do health systems actually make AI purchasing decisions?**
→ OPEN: CFO vs CMO vs CIO? If CMO clinical value pitch works, margin protection thesis wrong. Map decision flows at 5+ health systems.

**What is elasticity of health system software spending during margin compression?**
→ OPEN: If only high-performing systems (>10% margin) buy, TAM limited to 20-30% of market. Analyze spending by margin quartile.

**Will TEFCA enforcement create defensible moat for interoperability-native analytics?**
→ OPEN: If delayed 2+ years, EHR vendors improve native analytics first. Track ONC enforcement timeline.

**Which service lines have most room for AI efficiency gains?**
→ OPEN: If elective procedures already optimized, look elsewhere. Benchmark OR utilization rates.

---

## Evidence

| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12-18 | [[An Analysis of DRG Profitability]] | Research | Ortho 22%, cardiac 18-21% margins fund sepsis -15%, respiratory -19%. One spinal fusion = three sepsis cases. |
| 2025-12-21 | [[Financial Performance of U.S. Health Insurers]] | Research | UNH $6.5B cost overrun. Medical costs 7.5-8.5% trend. GLP-1: $50B extra pharmacy. VBC at 34% of MA (up from 10.3% in 2017). |
| 2025-12-08 | [[Will Detwiler and Emre Karatas]] | Operator | CFOs responding "top 3 priority" to margin analytics. Pain = fragmented data requiring manual stitching. |
| 2025-12-20 | [[Anu and Virtue]] | Operator | Common Spirit ($42B) only invests where they become customer. Customer validation as diligence filter. |
| 2025-12-20 | [[Nephron MA Medicaid Research Report]] | Research | MA margin trough: -2.0% pre-tax (worst in 25 years). MLR 91%. 50% EPS upside if margins recover to 4.5%. |
| 2025-12-20 | [[Comparing for-profit and not-for-profit health insurers]] | Research | For-profit: 500% RBC, 21.7% ROE, 3.2% margin. Nonprofit: 774% RBC, 2.3% ROE, 0.7% margin. |
